How DPP-4 Inhibitors Work: Protecting Your Body's Own Blood Sugar-Lowering Peptides
DPP-4 inhibitors treat type 2 diabetes by blocking the enzyme that destroys GLP-1 and GIP, the body's natural incretin peptides that control blood sugar after meals.
Quick Facts
What This Study Found
DPP-4 inhibitors work by blocking the enzyme dipeptidyl-peptidase IV, which normally breaks down the incretin hormones GLP-1 and GIP within minutes of their release. By preventing this degradation, DPP-4 inhibitors effectively increase the body's own GLP-1 and GIP levels, leading to improved insulin secretion, reduced glucagon release, and better blood glucose control — all in a glucose-dependent manner that minimizes hypoglycemia risk.
The first two approved DPP-4 inhibitors, sitagliptin and vildagliptin, demonstrated good efficacy and tolerability as oral medications for type 2 diabetes. Additional DPP-4 inhibitors were under review or in clinical development at the time of publication.
Key Numbers
2 approved DPP-4 inhibitors at time of publication (sitagliptin, vildagliptin) · 2 additional under regulatory review · Multiple others in clinical development · Oral administration · Target: DPP-4 enzyme that degrades GLP-1 and GIP
How They Did This
Expert review article covering the mechanism of action, development history, and physiological effects of DPP-4 inhibitors in the context of type 2 diabetes treatment. Published in Best Practice & Research Clinical Endocrinology & Metabolism.
Why This Research Matters
DPP-4 inhibitors represent a key intersection of peptide biology and diabetes treatment. Rather than injecting synthetic GLP-1 (like semaglutide or liraglutide), these oral drugs work by protecting the body's own incretin peptides from enzymatic destruction. Understanding how DPP-4 destroys GLP-1 and GIP — and how inhibiting this enzyme restores their function — is fundamental to understanding the entire incretin-based approach to diabetes treatment that has transformed the field.
The Bigger Picture
DPP-4 inhibitors were the first practical application of incretin biology in diabetes treatment. They paved the way for the GLP-1 receptor agonist revolution by proving that enhancing the incretin system could effectively treat type 2 diabetes. While GLP-1 receptor agonists have since taken center stage (especially for weight loss and cardiovascular protection), DPP-4 inhibitors remain widely prescribed — particularly for patients who prefer an oral medication with a gentler side effect profile.
What This Study Doesn't Tell Us
Published in 2009, this review covers only the early DPP-4 inhibitor landscape. Long-term safety data, cardiovascular outcomes, and comparisons with GLP-1 receptor agonists were not yet available. The review predates the explosion of GLP-1 agonists for obesity and cardiovascular protection that would later overshadow DPP-4 inhibitors in some clinical contexts.
Questions This Raises
- ?Why do GLP-1 receptor agonists produce greater weight loss and cardiovascular benefits than DPP-4 inhibitors, despite both working through the incretin system?
- ?Could combining DPP-4 inhibitors with GLP-1 agonists provide additional benefit, or do they work on the same pathway redundantly?
- ?Are there other important peptides beyond GLP-1 and GIP that DPP-4 degrades, and what are the implications of protecting them?
Trust & Context
- Key Stat:
- Minutes to hours DPP-4 normally destroys GLP-1 within minutes of release; DPP-4 inhibitors extend its active life, improving blood sugar control after meals
- Evidence Grade:
- This is an expert review from a respected endocrinology journal. The underlying science on DPP-4 enzyme activity and incretin biology is well-established. The clinical efficacy of DPP-4 inhibitors has since been extensively confirmed in large trials.
- Study Age:
- Published in 2009. The DPP-4 inhibitor class has since expanded to include saxagliptin, linagliptin, and alogliptin. The mechanism of action described remains accurate and unchanged.
- Original Title:
- Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
- Published In:
- Best practice & research. Clinical endocrinology & metabolism, 23(4), 479-86 (2009)
- Authors:
- Thornberry, Nancy A, Gallwitz, Baptist(2)
- Database ID:
- RPEP-01554
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What's the difference between DPP-4 inhibitors and GLP-1 drugs like Ozempic?
DPP-4 inhibitors (like Januvia) are pills that protect your body's own GLP-1 from being broken down. GLP-1 receptor agonists (like semaglutide/Ozempic) are injected synthetic versions of GLP-1 that are designed to resist DPP-4. GLP-1 agonists produce much higher GLP-1 activity levels, which is why they cause more weight loss and greater cardiovascular benefits — but also more side effects like nausea.
Can DPP-4 inhibitors cause low blood sugar?
One major advantage of DPP-4 inhibitors is that they work in a glucose-dependent manner — they boost insulin only when blood sugar is elevated, not when it's already normal. This means the risk of hypoglycemia (dangerously low blood sugar) is very low when used alone, unlike older diabetes drugs like sulfonylureas or insulin.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01554APA
Thornberry, Nancy A; Gallwitz, Baptist. (2009). Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).. Best practice & research. Clinical endocrinology & metabolism, 23(4), 479-86. https://doi.org/10.1016/j.beem.2009.03.004
MLA
Thornberry, Nancy A, et al. "Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).." Best practice & research. Clinical endocrinology & metabolism, 2009. https://doi.org/10.1016/j.beem.2009.03.004
RethinkPeptides
RethinkPeptides Research Database. "Mechanism of action of inhibitors of dipeptidyl-peptidase-4 ..." RPEP-01554. Retrieved from https://rethinkpeptides.com/research/thornberry-2009-mechanism-of-action-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.